Skip to Content

We are a focused organization with the expertise and insights to advance innovative new therapies.

With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases.

We develop high-potential molecules that have compelling safety and efficacy potential, and transform them into proprietary products that enable significant advances in patient care and outcomes.

We strive to meet our goals of improving patient quality of life, giving healthcare providers new treatment options, providing a collaborative environment for our employees and creating value for our shareholders.

Corporate Executive Team

Mark K. Oki

Mr. Oki has been Senior Vice President, Chief Financial Officer since February 2019, and was Chief Financial Officer from October 2015 to February 2019. Prior to joining VIVUS, Mr. Oki served as Chief Financial Officer of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from July 2012 to October 2015, as Principal Accounting Officer from May 2010 to October 2015, as Principal Financial Officer and Secretary from December 2011 to October 2015, as Vice President, Finance and Controller from February 2010 to July 2012, and as Controller from April 2006 to February 2010. From June 2001 to April 2006, Mr. Oki served as the Controller of Pharmacyclics, Inc., a publicly traded development stage pharmaceutical company. From 1998 to 2001, Mr. Oki held several positions at Incyte Genomics, Inc., now Incyte Corporation, a publicly traded company, including most recently as Assistant Controller. From 1992 to 1997, he held several positions at Deloitte & Touche LLP, a public accounting firm. Mr. Oki received a B.S. in Business Administration with a concentration in Accounting from San Jose State University.

 

Santosh T. Varghese

Dr. Varghese has been the company’s Senior Vice President, Chief Medical Officer since February 2020. Prior to that, beginning in January 2016, Dr. Varghese served as the company’s Vice President, Chief Medical Officer. From October 2013 to December 2015, Dr. Varghese served as the company’s Vice President, Medical & Regulatory Affairs, Pharmacovigilance, and QA. He joined the company in March 2012 as Vice President, Head of Medical Affairs. Prior to joining the company, Dr. Varghese was Senior Vice President, Medical Affairs at Élan Pharmaceuticals where he led Medical Affairs teams responsible for the BioNeurology portfolio. He held the position of Vice President Primary Care & Cardiovascular in Global Medical Affairs at Schering-Plough/Merck, and also held senior roles at Aventis/Sanofi-Aventis where he contributed to both US and global brand strategy and tactics. Dr. Varghese has served on the Board of Directors of the American Lung Association - New York and was on faculty at Touro University College of Medicine (now New York Medical College). Dr. Varghese earned his M.D. from St. George's University School of Medicine and a B.S. in Biology from Pennsylvania State University. He completed his medical training in the Caribbean, United States, and United Kingdom.

 

Deborah Larsen

Ms. Larsen has been Chief Strategy Officer (Commercial Operations) since August 2018. Prior to that, Ms. Larsen served as Chief Commercial Officer beginning in December 2016, and Vice President, Marketing overseeing Consumer and Professional Communications, Market Access and Business Analytics from January 2016 to December 2016. She joined VIVUS in February 2015 as Director of Marketing. Prior to joining VIVUS, Ms. Larsen held Global Marketing roles with GSK Consumer Healthcare from 2007 to 2014, with a leadership role in the obesity business since 2010. From 1996 to 2007, Ms. Larsen held the position of Sr. V.P., Management Supervisor at ICC, a Healthcare Communications Agency based in New Jersey. From 1987 to 1996, Ms. Larsen served in several Marketing and Brand Management positions at Novartis. From 2013 to 2014, Ms. Larsen also served on the Board of Directors for the Healthcare Businesswomen’s Association (HBA) Metro Chapter. Ms. Larsen has a B.S. in Biology from Ramapo College of New Jersey and an M.B.A. from Fairleigh Dickinson University.

 

Ted Broman

Mr. Broman has been Vice President, Chemistry, Manufacturing and Control since February 2009. Mr. Broman joined VIVUS in January 2006 as Senior Director, Chemistry, Manufacturing, and Control. Prior to joining VIVUS, Mr. Broman was Executive Director, Project Management at Durect, Inc. from 2001 to 2005. From 1994 to 2001, Mr. Broman held Senior Management positions in Operation and Project Management at Matrix Pharmaceutical, Inc. From 1988 to 1994 he was Director, Analytical Services at Cygnus, Inc. and from 1976 to 1988, Mr. Broman served in several positions in Syntex Laboratories, Syntex Chemicals Group, Corporate Quality Assurance, and Corporate Technical Services. Mr. Broman has a B.A. in Biochemistry and Molecular Biology from the University of California, Santa Barbara.

 

Thomas B. King

Thomas B. King has served as a director of the Company since May 24, 2017. Mr. King has been an independent biotechnology consultant since August 2016. From June 2003 to August 2016, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc., a publicly-traded pharmaceutical company. Prior to that, from September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a privately-held biopharmaceutical development-stage company. From January 1994 to February 2001, Mr. King held various senior executive positions at Anesta Corporation, a publicly-traded pharmaceutical company, including President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors until it was acquired by Cephalon, Inc., a publicly-traded biopharmaceutical company. Mr. King currently serves on the board of directors of Faraday Pharmaceuticals, Inc., Satsuma Pharmaceuticals, Inc., and Concentric Analgesics, Inc., all privately-held biotechnology companies. Mr. King also serves as a Venture Advisor at SPIRE Bioventures, a multi-disciplinary consortium aiding biotechnology entrepreneurs, and as an Advisory Board Member of the University of Colorado BioFrontiers Institute. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.

 

John Amos

John Amos has served as our Chief Executive Officer and a director of the Company since April 2018. From May 2017 to April 2018, he served as the Executive Chairman of Willow Biopharma Inc., a biopharmaceutical company. He served as the Chief Executive Officer of ORIX Healthcare Capital LLC, a private equity and venture capital investment company, from October 2012 to April 2017. Mr. Amos served as the Operating Partner and Portfolio Company Board Member of BioVeda China Fund, a financial investment company, from February 2008 to October 2012. He served as the Chief Executive Officer and President of the Oncology Therapeutics Network (acquired by McKesson Corporation in November 2007), a physician services company, from June 2005 to November 2007 and was a special advisor to McKesson Corporation, a public healthcare services company, from November 2007 to May 2008. Mr. Amos served as the President of the Oncology Therapeutics Network of Bristol Myers Squibb, a publicly traded biopharmaceutical company, from June 2003 to May 2005. He held executive roles in finance and technology in McKesson Corporation from March 1995 to April 2003. From 1991 to 2003, he served in the United States Air Force and the California Air National Guard in Tactical Fighter Operations. Mr. Amos has previously served on the board of directors of TD2, Navigating Cancer, CITIC Pharmaceuticals, Aesyntix Health, Prodigy Health, Apollo Health Street, Quinian Health, Oncology Therapeutics Network and Matawan Pharmaceuticals. Mr. Amos served as a member of the Scientific Advisory Board at MD Anderson Cancer Center Institute for Applied Cancer Science (IACS) and was a health policy advisor to Governor Jeb Bush’s 2016 Presidential Campaign. He has been appointed as a Trustee of the Global Leadership Council of the University of California, Davis Foundation. Mr. Amos has been named to the Information Week Top 500 CIO’s twice, won the Frost and Sullivan Award for Corporate Innovation. He studied Economics at the University of California, Davis and has a B.S. in General Business from the University of the State of New York.

 

Tracy Guo

Ms. Guo has been Vice President, Finance since February 2019. From October 2015 to February 2019, Ms. Guo served as our Controller. Ms. Guo joined VIVUS in September 2014 and served as Director, Financial Planning & Analysis. Prior to VIVUS, Ms. Guo served as Finance Director, Sales & Service of BD Biosciences from November 2012 to September 2014, and prior to this, she held various finance and Financial Planning & Analysis positions at Danaher Corporation – Molecular Devices, Brocade Communications, Medtronic – Spine & Biologics Division (formerly Kyphon), Phillips Electronics, and China TEDA Group. Ms. Guo received her B.A. from Tianjin Normal University, where she majored in English and minored in finance and an M.B.A from Thunderbird School of Global Management.

 

Other Links & Resources

You are about to leave the VIVUS LLC website

Links to third-party websites on VIVUS.com are provided solely for your convenience.

VIVUS LLC does not control the content contained on any third-party website linked from this website. Activities on third-party websites will be governed by the policies and terms of use of those third parties.